Single Supervisory Mechanism

Draft template for assessment report for the development of European herbal monographs and European Union list entries - Revision 6

Retrieved on: 
Thursday, April 18, 2024

The completed comments form should be sent to

Key Points: 
    • The completed comments form should be sent to
      [email protected]
      10
      11
      Keywords

      Committee on Herbal Medicinal Products; HMPC; European Union herbal
      monographs; European Union list of herbal substances, preparations and
      combinations thereof for use in traditional herbal medicinal products; herbal
      medicinal products; traditional herbal medicinal products; traditional use;
      well-established medicinal use; benefit-risk assessment; assessment report

      12

      1
      2

      Changes introduced in section 6 Overall conclusions.

    • Peer-reviewer

      If not the same peer-reviewer
      since last version, all peerreviewers should be listed, and
      the version specified in
      brackets.

    • 22

      23


      on
      .

    • It is a working

      24

      document, not yet edited, and shall be further developed after the release for consultation of the

      25


      .

    • The principle of the template is to make clear
      distinctions between presentation of data (methodology and results)
      and the assessment of the data (?assessor?s comment?).
    • likely from an article but it seems it is concluded by
      the rapporteur; ?According to the author? to be added.
    • Chapters with
      a heading including the word ?conclusion? should include a summary
      of all critical assessment of the assessor for that particular
      chapter.
    • If an assessor?s comment is not needed, the Rapporteur
      should delete the box inserted in the template.
    • ?
      The report should be sufficiently detailed to allow for secondary
      assessment of the available data by other HMPC experts.
    • Overview of available pharmacokinetic data regarding the herbal substance(s), herbal
      preparation(s) and relevant constituents thereof ........................................................... 16

      97
      98

      3.3.

    • Overall conclusions on clinical pharmacology and efficacy ........................................ 27

      Assessment report on
      EMA/HMPC/418902/2005

      Page 4/41

      119

      5.

    • This sections is related to
      available quality standards and there is no need to repeat information
      on all preparations included in the monograph.
    • Search and assessment methodology

      161

      The Rapporteur shall undertake a comprehensive search of relevant
      scientific literature and articles, Acts of law and regulations and
      other relevant sources.

    • Cross-reference to the list of
      references in Annex, which should list separately the references
      supporting the assessment report.
    • 143
      144
      145

      150
      151
      152
      153
      154

      162
      163
      164
      165
      166
      167
      168
      169
      170
      171
      172
      173
      174
      175

      Herbal substance(s)

      Herbal preparation(s)

      Relevant constituents for this assessment report

      Examples of scientific databases to be searched are Medline, PubMed,
      Cochrane Database of Systematic Reviews, EMBASE etc.

    • Assessment report on
      EMA/HMPC/418902/2005

      Page 6/41

      176
      177
      178
      179
      180
      181
      182
      183
      184
      185
      186
      187
      188
      189
      190
      191
      192

      Additional relevant references could also be retrieved from the checked
      references.

    • Examples of books are Hagers Handbuch, The Complete German
      Commission E Monographs, PDR for herbal medicines etc.
    • In addition, information from non-EU regulatory
      authorities for examples Health Canada monographs or WHO monographs
      could be searched, if relevant to herbal substances and preparations in
      EU.
    • 221

      225
      226
      227

      232

      When the assessment report is revised, the rapporteur should briefly
      summarise the main changes under this section.

    • Data are collected using the template entitled ?Document
      for information exchange for the preparation of the assessment report
      for the development of European Union monographs and for inclusion of
      herbal substance(s), preparation(s) or combinations thereof in the
      list? (EMEA/HMPC/137093/2006).
    • Assessment report on
      EMA/HMPC/418902/2005

      Page 8/41

      Herbal substance/

      Indication

      Posology and
      method of

      preparation

      administration

      Posology, age
      groups,
      pharmaceutical
      form, method of
      administration,
      duration of use
      As reported in
      the market
      overview

      As reported in
      the market
      overview

      As reported in
      the market
      overview.

    • Assessment report on
      EMA/HMPC/418902/2005

      Page 10/41

      Herbal substance/

      Indication/Medicinal

      Posology and

      preparation

      use

      method of
      administration

      Posology, age
      groups,
      pharmaceutical
      form, method of
      administration,
      duration of use

      Regulatory Status

      Type of
      regulatory
      status where
      possible, date,
      Country

      287

      This overview is not exhaustive.

    • Clinical Safety/Pharmacovigilance

      836
      837
      838
      839
      840
      841

      See ?Assessment of clinical safety and efficacy in the preparation of
      EU herbal monographs for well-established and traditional herbal
      medicinal products?(EMA/HMPC/104613/2005) for further details.

    • Overall conclusions on clinical safety

      1067

      1068

      In terms of structure, the conclusion should follow the presentation of
      the results above.

    • Overall conclusions

      1092

      1093

      1101

      Describe key aspects only briefly, these will already have been
      described in detail in the respective sections.

    • This section should
      cover all recommended ?well-established use? and ?traditional use?
      indications and conclusions shall be provided for each therapeutic
      indication and each herbal preparation.
    • 1102

      Well established use monograph

      1103
      1104

      The clinical studies supporting well-established use should be
      specified for each therapeutic indication and each herbal preparation.

    • The choice for the wording of traditional use indications vis-?vis existing wordings in monographs in the same therapeutic area should
      be briefly discussed/justified.
    • 1153

      List entry

      1154

      The conclusions should include a statement pointing to the
      possibility/non-possibility to support a European Union list entry.

Compilation of quality review of documents (QRD) on stylistic matters in product information

Retrieved on: 
Sunday, March 10, 2024

29 February 2024

Key Points: 
    • 29 February 2024
      EMA/25090/2002 rev.23*
      Human Medicines Division

      Compilation of QRD decisions on stylistic matters in product information
      Issues
      Abbreviations

      Connected problems
      Subscript and superscript

      QRD Suggestions
      Acronyms must be written in their standard form; e.g.

    • Cmax, Cmax
      Abbreviations and

      Not always understood,

      Non-standard abbreviations and acronyms should be avoided, and the term should be written out in full.

    • The same applies when stating the pharmaceutical form in section 3 of the SmPC and section 4 of the labelling;
      i.e.
    • critical steps prior to administration of the product should also be included (section 5 of Annex IIIA).
    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 2/23

      Issues

      Connected problems

      QRD Suggestions

      emphasise in the labelling
      the special handling prior
      to administration of the
      product.

    • Consistency

      Inconsistencies in style are

      Once a particular style or house style has been selected, it must be used consistently throughout the text.

    • Tradename 150 mg solution for injection in pre-filled syringe
      Tradename 150 mg solution for injection in pre-filled pen

      information annexes?

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 3/23

      Issues
      Desiccant

      Connected problems

      QRD Suggestions

      For medicinal products

      The foil of blister packs containing a desiccant must be clearly labelled to show which blister pocket contains

      packaged with a desiccant

      the desiccant.

    • For bottles containing a desiccant, a similar statement should also be considered provided there

      mistake the desiccant for a

      is available space.

    • It can only be included in brackets in section 3 of the

      where can this be

      SmPC and section 4 of the labelling.

    • Direct speech should only
      be used in section 6 of the SmPC for instructions about shelf-life, storage, handling and disposal.
    • The term ?drug? though can be used in the product information annexes when it is part of a standard set of
      terms (e.g.
    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 5/23

      Issues
      Foreign terms

      Connected problems

      QRD Suggestions

      Foreign terms, particularly

      Foreign terms must be written in italics; e.g.

    • Patients can be referred to as ?he? or

      physician is often referred

      as ?she? when the medicinal product is exclusively for use by males or females.

    • if the product in question might be

      measurements are

      used by elderly patients), in brackets after the metric measures in the English text.

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 6/23

      Issues

      Connected problems

      QRD Suggestions

      product name is composed
      of MAH+INN?

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 7/23

      Issues

      Connected problems

      QRD Suggestions
      MT: English
      BG: Bulgarian
      NL: Dutch
      CZ: Czech or English at applicant?s discretion.

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 14/23

      Issues

      Connected problems

      QRD Suggestions
      considered, e.g.

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 16/23

      Issues
      Symbols: Non-Unicode

      Connected problems

      QRD Suggestions

      The use of non-Unicode

      Only Unicode symbols must be used in submitted product information annexes.

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 20/23

      Issues

      Connected problems

      Units: SI base units -

      International Standard

      litre

      base units have been
      introduced in the European
      Union with Council
      Directive 80/181/EEC of
      20.12.79 (O.J.

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 23/23

ION LookOut named "Best Solution for Records Retention" at RegTech Insight Awards APAC 2024

Retrieved on: 
Thursday, March 7, 2024

LONDON, March 7, 2024 /PRNewswire-PRWeb/ --ION, a leading global provider of mission-critical trading and workflow automation and risk management software to financial institutions that deal in asset management, cleared derivatives, equities, fixed income, foreign exchange, and secured funding, announces that ION LookOut has been named "Best Solution for Records Retention" by RegTech Insight Awards APAC 2024.

Key Points: 
  • LONDON, March 7, 2024 /PRNewswire-PRWeb/ -- ION , a leading global provider of mission-critical trading and workflow automation and risk management software to financial institutions that deal in asset management, cleared derivatives, equities, fixed income, foreign exchange, and secured funding, announces that ION LookOut has been named "Best Solution for Records Retention" by RegTech Insight Awards APAC 2024.
  • LookOut, developed by LIST – an ION company – is a multi-asset solution for record-keeping to which users can add market surveillance, regulatory reporting, and business analytics.
  • "Naming LookOut as the Best Solution for Records Retention reflects ION's commitment to delivering innovative solutions to meet our customers' evolving needs," said Alvise Insalaco, Chief Executive Officer: LIST.
  • "The solution can process large amounts of data and offers a workflow management system with built-in connectivity for reporting entities and National Competent Authorities."

ESMA and NCAs to coordinate supervisory activities on MiFID II pre-trade controls

Retrieved on: 
Sunday, January 14, 2024

ESMA and NCAs to coordinate supervisory activities on MiFID II pre-trade controls

Key Points: 
  • ESMA and NCAs to coordinate supervisory activities on MiFID II pre-trade controls
    The European Securities and Markets Authority (ESMA), the EU’s financial markets regulator and supervisor, has launched a Common Supervisory Action (CSA) with National Competent Authorities (NCAs), with the objective of assessing the implementation of pre-trade controls (PTCs) by EU investment firms using algorithmic trading techniques.
  • PTCs are used by investment firms to carry out checks at order entry to limit and prevent sending erroneous orders for execution to trading venues.
  • Following the May 2022 flash crash, ESMA and NCAs have focussed their attention on the implementation of PTCs in the EU, gathering evidence through questionnaires submitted to a sample of EU investment firms.
  • As a follow up, ESMA and NCAs have decided to launch a CSA with the goal of gathering further and more detailed insights on how firms are using PTCs across the EU.

FinTech Global lists ION products in the RegTech 100 list for second consecutive year

Retrieved on: 
Wednesday, December 6, 2023

LONDON, Dec. 6, 2023 /PRNewswire-PRWeb/ -- ION, a global leader in trading and workflow automation software, high-value analytics and insights, and strategic consulting to financial institutions, central banks, governments, and corporates, announces that FinTech Global has listed three of its products in the RegTech 100 list for 2024.

Key Points: 
  • LONDON, Dec. 6, 2023 /PRNewswire-PRWeb/ -- ION , a global leader in trading and workflow automation software, high-value analytics and insights, and strategic consulting to financial institutions, central banks, governments, and corporates, announces that FinTech Global has listed three of its products in the RegTech 100 list for 2024.
  • The RegTech100 is an annual list of 100 of the world's most innovative RegTech companies.
  • The ION products listed – XTP Risk JANUS , XTP Central Limits , and LookOut – are real-time risk management and surveillance systems.
  • Mirko Marcadella, Chief Product and Marketing Officer at LIST, said, "For the second consecutive year, ION has secured a coveted spot on the RegTech 100 list.

Riverside Insights and CAI Founders to Host Virtual Conference on SLD Identification

Retrieved on: 
Tuesday, November 28, 2023

ITASCA, Ill., Nov. 28, 2023 /PRNewswire-PRWeb/ -- Riverside Insights®, a leading developer of research-based assessments and analytics, today announced it is teaming up with Dr. Dawn P. Flanagan, Dr. Vincent C. Alfonso and Dr. Samuel O. Ortiz, creators of the Cross-Battery Assessment Approach and founders of Comprehensive Assessment for Intervention (CAI), to host their first annual virtual conference featuring researchers, scholars, and educators dedicated to advancing the field of specific learning disabilities (SLD) identification and intervention. The CAI Conference - State of the Art of SLD Identification: Innovations in Theory, Research, and Practice - will take place January 25-26, 2024, and enable participants to earn continuing education (CE) credit.

Key Points: 
  • Dawn P. Flanagan, Dr. Vincent C. Alfonso and Dr. Samuel O. Ortiz, creators of the Cross-Battery Assessment Approach and founders of Comprehensive Assessment for Intervention (CAI), to host their first annual virtual conference featuring researchers, scholars, and educators dedicated to advancing the field of specific learning disabilities (SLD) identification and intervention.
  • The CAI Conference - State of the Art of SLD Identification: Innovations in Theory, Research, and Practice - will take place January 25-26, 2024, and enable participants to earn continuing education (CE) credit.
  • CAI 2024 brings together a premier line-up of world-renowned presenters including researchers, scholars, and educators dedicated to advancing the field of SLD identification and intervention.
  • "CAI 2024 brings together a premier line-up of world-renowned presenters including researchers, scholars, and educators dedicated to advancing the field of SLD identification and intervention," said Dr. Sarah Holman, director, Riverside Insights.

The EBA publishes 2023 list of third country groups and third country branches operating in the EU/EEA

Retrieved on: 
Tuesday, October 17, 2023

The EBA publishes 2023 list of third country groups and third country branches operating in the EU/EEA

Key Points: 
  • The EBA publishes 2023 list of third country groups and third country branches operating in the EU/EEA
    04 October 2023
    The European Banking Authority (EBA) published today the updated list of all third country groups (TCGs) with intermediate EU parent undertakings IPU(s), where applicable, and the list of all third country branches (TCBs) operating in the European Union and European Economic Area (EU/EEA).
  • This publication ensures that market participants have clarity on the direct ownership of the involved institutions.
  • In the course of the 2023 exercise, 461 TCGs from 47 third countries have been identified as operational in the EU/EEA.
  • Moreover, 65 TCGs have branches in the EU/EEA with a total of 105 third country branches of credit institutions operating in the EU/EEA.

ESMA to launch Common Supervisory Action on MiFID II sustainability requirements

Retrieved on: 
Tuesday, October 3, 2023

ESMA to launch Common Supervisory Action on MiFID II sustainability requirements

Key Points: 
  • ESMA to launch Common Supervisory Action on MiFID II sustainability requirements
    The European Securities and Markets Authority (ESMA), the EU’s financial markets regulator and supervisor, will launch a Common Supervisory Action (CSA) with National Competent Authorities (NCAs) on the integration of sustainability in firms’ suitability assessment and product governance processes and procedures in 2024.
  • The goal of the CSA will be to assess the progress made by intermediaries in the application of the key sustainability requirements, which entered into application in 2022 following the amendments to the MiFID II Delegated Acts.
  • ESMA believes this initiative, and the related sharing of practices across NCAs, will help ensure consistent application of EU rules and enhance the protection of investors in line with ESMA’s objectives.
  • The CSA follows ESMA’s recent update of two sets of guidelines on suitability and product governance, both of which enter into application today.

ESAs analyse the extent of voluntary disclosure of principal adverse impacts under the SFDR

Retrieved on: 
Friday, September 29, 2023

ESAs analyse the extent of voluntary disclosure of principal adverse impacts under the SFDR

Key Points: 
  • ESAs analyse the extent of voluntary disclosure of principal adverse impacts under the SFDR
    The Joint Committee of the three European Supervisory Authorities (EBA, EIOPA and ESMA – the ESAs) today published their second annual Report on the extent of voluntary disclosure of principal adverse impacts under the Article 18 of the Sustainable Finance Disclosure Regulation (SFDR).
  • - When financial market participants do not consider principal adverse impacts, they should better explain the reasons for not doing so.
  • Background
    Principal Adverse Impacts (PAI) are the most significant negative impacts of investments on the environment and people.
  • When a financial market participant considers principal adverse impacts, it means that it should seek to reduce the negative impact of the companies they invest in.